A Food and Drug Administration advisory panel today voted unanimously to recommend an extra Moderna booster dose for certain individuals. The Vaccines and Related Biological Products Advisory Committee recommended boosters for previous Moderna recipients age 65 and older, plus individuals age 18-64 if they are at high risk of severe COVID-19 or whose frequent institutional or occupational exposure puts them at high risk of serious complications, including severe COVID-19. The committee Friday will consider Johnson & Johnson boosters. Moderna’s request is now slated for consideration by the Centers for Disease Control and Prevention.

Related News Articles

Headline
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention…
Headline
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969…
Headline
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Centers for Disease Control and Prevention yesterday released an operational planning guide for pediatric COVID-19 vaccination and preliminary information…